Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
July 15, 2021
Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets - Implications for quality control and application
Heino Stass, Sarah Just, Boris Weimann, et al.
Clinical Pharmacokinetics
|
August 6, 2013
Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban
Stefan Willmann, Corina Becker, Rolf Burghaus, et al.
British Journal of Clinical Pharmacology
|
July 19, 2011
Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling
Olaf Weber, Stefan Willmann, Hilmar Bischoff, et al.
Journal of Clinical Pharmacology
|
January 26, 2019
Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study
Heino Stass, John Lettieri, Konstantina M Vanevski, et al.
British Journal of Clinical Pharmacology
|
August 25, 2015
Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds
Amit A Somani, Kirstin Thelen, Songmao Zheng, et al.
The Pediatric Infectious Disease Journal
|
January 23, 2018
Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study
Stefan Wirth, Sherif G S Emil, Arnis Engelis, et al.
Thrombosis Journal
|
December 12, 2018
Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
Stefan Willmann, Kirstin Thelen, Dagmar Kubitza, et al.
Clinical and Translational Science
|
April 2, 2024
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers
Tianxing Liu, Kensei Hashizume, Eva Krieg, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 19, 2024
Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data
Stefan Willmann, Adam Lloyd, Rupert Austin, et al.
Pediatric Pulmonology
|
December 12, 2022
Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension
Stefan Willmann, Andrea Kerstin Keller, Michaela Meyer, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
July 15, 2021
Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets - Implications for quality control and application
Heino Stass, Sarah Just, Boris Weimann, et al.
Clinical Pharmacokinetics
|
August 6, 2013
Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban
Stefan Willmann, Corina Becker, Rolf Burghaus, et al.
British Journal of Clinical Pharmacology
|
July 19, 2011
Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling
Olaf Weber, Stefan Willmann, Hilmar Bischoff, et al.
Journal of Clinical Pharmacology
|
January 26, 2019
Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study
Heino Stass, John Lettieri, Konstantina M Vanevski, et al.
British Journal of Clinical Pharmacology
|
August 25, 2015
Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds
Amit A Somani, Kirstin Thelen, Songmao Zheng, et al.
The Pediatric Infectious Disease Journal
|
January 23, 2018
Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study
Stefan Wirth, Sherif G S Emil, Arnis Engelis, et al.
Thrombosis Journal
|
December 12, 2018
Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
Stefan Willmann, Kirstin Thelen, Dagmar Kubitza, et al.
Clinical and Translational Science
|
April 2, 2024
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers
Tianxing Liu, Kensei Hashizume, Eva Krieg, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 19, 2024
Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data
Stefan Willmann, Adam Lloyd, Rupert Austin, et al.
Pediatric Pulmonology
|
December 12, 2022
Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension
Stefan Willmann, Andrea Kerstin Keller, Michaela Meyer, et al.
Page
of 8